Arcus Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RCUS New York 2836 www.arcusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcus Biosciences, Inc.

Arcus Biosciences (RCUS) Valuation Check After Recent Share Price Pullback And 1 Year Gain - Jan 10th, 2026 9:09 am
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs - Jan 7th, 2026 2:05 pm
TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines - Jan 6th, 2026 7:13 am
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return - Jan 5th, 2026 7:24 pm
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Dec 18th, 2025 2:05 pm
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? - Dec 17th, 2025 5:30 am
RCUS Stock Down on Decision to Discontinue GILD Partnered Study - Dec 15th, 2025 7:59 am
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next - Dec 14th, 2025 9:10 am
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak - Dec 12th, 2025 2:05 pm
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio - Dec 12th, 2025 6:30 am
Arcus cancels work on Gilead-partnered cancer combo after trial setback - Dec 12th, 2025 4:47 am
Arcus Biosciences Announces New Employment Inducement Grants - Dec 9th, 2025 4:00 pm
An Intrinsic Calculation For Arcus Biosciences, Inc. (NYSE:RCUS) Suggests It's 39% Undervalued - Nov 28th, 2025 7:49 am
Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Nov 18th, 2025 2:05 pm
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target Price - Nov 1st, 2025 8:34 am
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - Oct 30th, 2025 9:35 pm
Arcus Biosciences Announces Commencement of Public Offering of Common Stock - Oct 30th, 2025 2:01 pm
Why Arcus Biosciences (RCUS) May Be Banking on Partnerships to Accelerate Its Immuno-Oncology Pipeline - Oct 30th, 2025 8:15 am
Arcus Biosciences (RCUS): Losses Widen 26% Annually, Revenue Growth Projections Test Bullish Outlook - Oct 29th, 2025 4:12 pm
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates - Oct 28th, 2025 3:55 pm